Gangning Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1756105/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429, 457-463.	27.8	2,833
2	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 2006, 9, 435-443.	16.8	1,253
3	DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell, 2015, 162, 961-973.	28.9	1,075
4	Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. Cancer Cell, 2014, 26, 577-590.	16.8	959
5	The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Research, 1999, 27, 2291-2298.	14.5	765
6	Rethinking how DNA methylation patterns are maintained. Nature Reviews Genetics, 2009, 10, 805-811.	16.3	693
7	DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Molecular Cancer Therapeutics, 2009, 8, 1579-1588.	4.1	518
8	Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements. Molecular and Cellular Biology, 2002, 22, 480-491.	2.3	508
9	Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7357-7362.	7.1	435
10	The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2. Cancer Research, 2009, 69, 2623-2629.	0.9	381
11	Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Research, 2012, 22, 2497-2506.	5.5	381
12	Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12979-12984.	7.1	325
13	Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Research, 2002, 62, 6456-61.	0.9	310
14	Preferential response of cancer cells to zebularine. Cancer Cell, 2004, 6, 151-158.	16.8	282
15	Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer. PLoS Genetics, 2010, 6, e1000917.	3.5	252
16	DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival. Cancer Cell, 2012, 21, 655-667.	16.8	240
17	Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochemical and Biophysical Research Communications, 2009, 379, 726-731.	2.1	214
18	Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells. Molecular and Cellular Biology, 2004, 24, 1270-1278.	2.3	205

#	Article	IF	CITATIONS
19	Delivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides. Cancer Research, 2007, 67, 6400-6408.	0.9	204
20	Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Molecular Cancer Therapeutics, 2005, 4, 1515-1520.	4.1	203
21	Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients. Clinical Cancer Research, 2004, 10, 7457-7465.	7.0	202
22	Role of Nucleosomal Occupancy in the Epigenetic Silencing of the MLH1 CpG Island. Cancer Cell, 2007, 12, 432-444.	16.8	189
23	Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14080-14085.	7.1	186
24	Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA. Molecular and Cellular Biology, 2009, 29, 5366-5376.	2.3	179
25	DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Human Molecular Genetics, 2011, 20, 4299-4310.	2.9	172
26	Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10238-10244.	7.1	171
27	Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene, 2002, 21, 6694-6702.	5.9	165
28	Polycomb-Repressed Genes Have Permissive Enhancers that Initiate Reprogramming. Cell, 2011, 147, 1283-1294.	28.9	161
29	Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Research, 2002, 62, 961-6.	0.9	158
30	Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. Molecular Cancer Research, 2004, 2, 62-72.	3.4	151
31	Unique DNA Methylation Patterns Distinguish Noninvasive and Invasive Urothelial Cancers and Establish an Epigenetic Field Defect in Premalignant Tissue. Cancer Research, 2010, 70, 8169-8178.	0.9	148
32	H2A.Z Maintenance during Mitosis Reveals Nucleosome Shifting on Mitotically Silenced Genes. Molecular Cell, 2010, 39, 901-911.	9.7	136
33	Susceptibility of Nonpromoter CpG Islands to De Novo Methylation in Normal and Neoplastic Cells. Journal of the National Cancer Institute, 2001, 93, 1465-1472.	6.3	134
34	Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. International Journal of Cancer, 2009, 125, 723-729.	5.1	134
35	The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome. Genes, 2019, 10, 172.	2.4	134
36	DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Research, 2008, 36, 4689-4698.	14.5	133

#	Article	IF	CITATIONS
37	Examination of <i>IGF2</i> and <i>H19</i> Loss of Imprinting in Bladder Cancer. Cancer Research, 2007, 67, 10753-10758.	0.9	127
38	OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14497-14502.	7.1	117
39	Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nature Reviews Urology, 2005, 2, 502-510.	1.4	110
40	Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. European Journal of Cancer, 2005, 41, 2769-2778.	2.8	109
41	DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nature Communications, 2016, 7, 11453.	12.8	109
42	DNA methylation enables transposable element-driven genome expansion. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19359-19366.	7.1	109
43	miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene, 2013, 32, 4694-4701.	5.9	108
44	Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. Molecular Cell, 2016, 62, 422-431.	9.7	106
45	Nucleosomes Containing Methylated DNA Stabilize DNA Methyltransferases 3A/3B and Ensure Faithful Epigenetic Inheritance. PLoS Genetics, 2011, 7, e1001286.	3.5	103
46	DNA Methylation Differences Associated with Tumor Tissues Identified by Genome Scanning Analysis. Genomics, 1998, 53, 260-268.	2.9	100
47	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics, 2017, 12, 416-432.	2.7	98
48	Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood, 2012, 119, 206-216.	1.4	97
49	The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Human Molecular Genetics, 2001, 10, 903-910.	2.9	87
50	Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells. Cancer Research, 2018, 78, 5754-5766.	0.9	83
51	Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses. Genome Research, 2018, 28, 1147-1157.	5.5	82
52	Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Research, 2013, 41, 3973-3985.	14.5	77
53	A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence. Clinical Cancer Research, 2014, 20, 1978-1989.	7.0	77
54	The Role of DNA Methylation in Cancer. Advances in Experimental Medicine and Biology, 2016, 945, 151-172.	1.6	76

#	Article	IF	CITATIONS
55	Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Molecular Cancer Research, 2004, 2, 62-72.	3.4	74
56	Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Reviews in Allergy and Immunology, 2014, 47, 128-135.	6.5	71
57	PAX6 methylation and ectopic expression in human tumor cells. International Journal of Cancer, 2000, 87, 179-185.	5.1	69
58	Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. Nature Protocols, 2007, 2, 1931-1936.	12.0	69
59	Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods, 2002, 27, 150-155.	3.8	62
60	Locus-Wide Chromatin Remodeling and Enhanced Androgen Receptor-Mediated Transcription in Recurrent Prostate Tumor Cells. Molecular and Cellular Biology, 2006, 26, 7331-7341.	2.3	62
61	Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblonâ€independent manner. Molecular Oncology, 2018, 12, 180-195.	4.6	62
62	Structure of nucleosome-boundÂDNA methyltransferases DNMT3A and DNMT3B. Nature, 2020, 586, 151-155.	27.8	61
63	Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the Transcriptome. PLoS ONE, 2010, 5, e12994.	2.5	57
64	RUNX3 Methylation Reveals that Bladder Tumors Are Older in Patients with a History of Smoking. Cancer Research, 2008, 68, 6208-6214.	0.9	55
65	Gene Reactivation by 5-Aza-2′-Deoxycytidine–Induced Demethylation Requires SRCAP–Mediated H2A.Z Insertion to Establish Nucleosome Depleted Regions. PLoS Genetics, 2012, 8, e1002604.	3.5	52
66	Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene, 2002, 298, 91-99.	2.2	51
67	Genetic and Epigenetic Alterations in Bladder Cancer. International Neurourology Journal, 2016, 20, S84-94.	1.2	49
68	Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGIâ€110) in Hepatocellular Carcinoma. Hepatology, 2018, 68, 1412-1428.	7.3	48
69	Linker histone H1.2 establishes chromatin compaction and gene silencing through recognition of H3K27me3. Scientific Reports, 2015, 5, 16714.	3.3	44
70	A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. Blood, 2018, 131, 1145-1148.	1.4	44
71	SNF5 Is an Essential Executor of Epigenetic Regulation during Differentiation. PLoS Genetics, 2013, 9, e1003459.	3.5	43
72	Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biology, 2017, 18, 3.	8.8	43

#	Article	IF	CITATIONS
73	Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. Cancer Letters, 2017, 401, 11-19.	7.2	42
74	Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics, 2018, 8, 4520-4534.	10.0	40
75	Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics, 2011, 6, 450-464.	2.7	39
76	Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer, 2013, 13, 275.	2.6	39
77	The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the Polycomb group protein EZH2 in cancer. Cell Cycle, 2009, 8, 2313-2314.	2.6	35
78	Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Scientific Reports, 2017, 7, 40636.	3.3	35
79	Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells. PLoS ONE, 2013, 8, e75136.	2.5	33
80	CT prediction of the Fuhrman grade of clear cell renal cell carcinoma (RCC): towards the development of computer-assisted diagnostic method. Abdominal Imaging, 2015, 40, 3168-3174.	2.0	33
81	Mother–child transmission of epigenetic information by tunable polymorphic imprinting. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11970-E11977.	7.1	33
82	Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine. Cancer Research, 2020, 80, 2441-2450.	0.9	33
83	Reaction of N-(2-Chloroethyl)-N-nitrosoureas with DNA:  Effect of Buffers on DNA Adduction, Cross-Linking, and Cytotoxicity. Chemical Research in Toxicology, 1996, 9, 208-214.	3.3	32
84	Role of Electrostatics in the Sequence-Selective Reaction of Charged Alkylating Agents with DNA. Journal of the American Chemical Society, 1995, 117, 10135-10136.	13.7	31
85	Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. Scientific Reports, 2017, 7, 41947.	3.3	29
86	Identification of DNA Methylation–Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. Cancer Research, 2016, 76, 1954-1964.	0.9	28
87	Tissue Inhibitor of Metalloproteinase 1 Expression Associated with Gene Demethylation Confers Anoikis Resistance in Early Phases of Melanocyte Malignant Transformation. Translational Oncology, 2009, 2, 329-340.	3.7	26
88	Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics, 2018, 19, 369.	2.6	26
89	Regioselective Effect of Zwitterionic DNA Substitutions on DNA Alkylation:Â Evidence for a Strong Side Chain Orientational Preferenceâ€. Biochemistry, 1997, 36, 6024-6032.	2.5	25
90	Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications. Advances in Urology, 2012, 2012, 1-11.	1.3	24

#	Article	IF	CITATIONS
91	Quantitative Contour Analysis as an Image-based Discriminator Between Benign and Malignant Renal Tumors. Urology, 2018, 114, 121-127.	1.0	23
92	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
93	Novel endothelin B receptor transcripts with the potential of generating a new receptor. Gene, 1999, 228, 43-49.	2.2	20
94	Lysine methyltransferase G9a is not required for DNMT3A/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells. Epigenetics and Chromatin, 2012, 5, 3.	3.9	20
95	Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. Genes, 2015, 6, 977-990.	2.4	19
96	DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines. Oncogene, 2000, 19, 943-952.	5.9	17
97	Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers. Oncotarget, 2017, 8, 5439-5448.	1.8	17
98	Reprogramming of the human intestinal epigenome by surgical tissue transposition. Genome Research, 2014, 24, 545-553.	5.5	16
99	Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine. Scientific Reports, 2016, 6, 24545.	3.3	15
100	Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. Clinical Epigenetics, 2021, 13, 84.	4.1	15
101	Epigenetic landscape change analysis during human EMT sheds light on a key EMT mediator TRIM29. Oncotarget, 2017, 8, 98322-98335.	1.8	13
102	Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. Genome Medicine, 2021, 13, 130.	8.2	12
103	Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation. Hepatology, 2019, 69, 2652-2663.	7.3	10
104	Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype. International Journal of Cancer, 2020, 146, 3065-3076.	5.1	10
105	Creating a flexible multiple microRNA expression vector by linking precursor microRNAs. Biochemical and Biophysical Research Communications, 2011, 411, 276-280.	2.1	9
106	epiG: statistical inference and profiling of DNA methylation from whole-genome bisulfite sequencing data. Genome Biology, 2017, 18, 38.	8.8	6
107	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	1.6	6
108	A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer. Frontiers in Oncology, 2021, 11, 614927.	2.8	5

#	ARTICLE	IF	CITATIONS
109	FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers, 2022, 14, 1717.	3.7	5
110	Alterations in Deoxyribonucleic Acid (DNA) Methylation Patterns of Calca, Timp3, Mmp2, and Igf2r Are Associated With Chronic Cystitis in a Cyclophosphamide-induced Mouse Model. Urology, 2013, 82, 253.e9-253.e15.	1.0	4
111	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	2.8	4
112	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A metaâ€analysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	5.1	4
113	The Human Epigenome. , 2012, , 5-20.		3
114	Epi Meets Genomics: Technologies for Finding and Reading the 5th Base. , 2005, , 39-64.		2
115	Epigenetics of Melanoma. , 2015, , 339-361.		1
116	PAX6 methylation and ectopic expression in human tumor cells. , 2000, 87, 179.		1
117	Outlining the limits of partial nephrectomy. Translational Andrology and Urology, 2015, 4, 294-300.	1.4	1
118	Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients. Molecular Oncology, 2022, 16, 1913-1930.	4.6	1
119	Unique Role for a DNA Methyltransferase Isoform in Lung Cancer. EBioMedicine, 2015, 2, 1272-1273.	6.1	0
120	Rethinking Demethylating Agents in Epigenetic Cancer Therapy. Journal of Molecular Pharmaceutics & Organic Process Research, 2016, 4, .	2.0	0
121	Epigenetic Silencing of a Novel Candidate Tumor Suppressor "miR―Predicts Poor Prognosis In High-Risk MDS and AML Blood, 2010, 116, 3629-3629.	1.4	0
122	Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,. Blood, 2011, 118, 3450-3450.	1.4	0
123	Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy. Blood, 2016, 128, 3258-3258.	1.4	0
124	Abstract 3736: SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma. Cancer Research, 2022, 82, 3736-3736.	0.9	0